huCART19-IL18-eDHFR cells therapy (University of Pennsylvania)

N/A

Report date: 2026/01/16 20:01:23

Base Information

Drug NamehuCART19-IL18-eDHFR cells therapy (University of Pennsylvania)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsInterleukin 18 modulators

TargetsB-lymphocyte antigen CD19Interleukin 18

Therapy Area/IndicationsLymphoma, Follicular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Pennsylvania

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Pennsylvania

Inactive CompaniesN/A

Active IndicationsLymphoma, Follicular

Inactive IndicationsN/A

Other Information

ATC CodeN/A